Vaccine nanotechnology
First Claim
1. Nanoparticles having a geometric diameter of between greater than 60 nm and less than 250 nm, and formed of one or more polymers selected from the group consisting of polyesters, polyhydroxacids, poly(orthoesters);
- polyanhydrides, polyalkylene oxides, and copolymers thereof,wherein the nanoparticles selectively target the subcapsular macrophages and dendritic cells in the draining lymph nodes, andwherein the nanoparticles comprisea dendritic cell immunomodulatory agent selected from the group consisting of toll-like receptor agonists, CD40 agonists, and agents which promote dendritic cell maturation; and
a T cell peptide antigen for processing by dendritic cells and presentation with major histocompatibility complex (MHC) to T cells.
10 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides vaccine nanocarriers capable of stimulating an immune response in T cells and/or B cells, in some embodiments, comprising at least one immunomodulatory agent, and optionally comprising at last one targeting moiety and optionally at least one immunostimulatory agent. The invention provides pharmaceutical compositions comprising inventive vaccine nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive vaccine nanocarriers and pharmaceutical compositions thereof. The invention provides methods of prophylaxis and/or treatment of diseases, disorders, and conditions comprising administering at least one inventive vaccine nanocarrier to a subject in need thereof.
-
Citations
21 Claims
-
1. Nanoparticles having a geometric diameter of between greater than 60 nm and less than 250 nm, and formed of one or more polymers selected from the group consisting of polyesters, polyhydroxacids, poly(orthoesters);
- polyanhydrides, polyalkylene oxides, and copolymers thereof,
wherein the nanoparticles selectively target the subcapsular macrophages and dendritic cells in the draining lymph nodes, and wherein the nanoparticles comprise a dendritic cell immunomodulatory agent selected from the group consisting of toll-like receptor agonists, CD40 agonists, and agents which promote dendritic cell maturation; and a T cell peptide antigen for processing by dendritic cells and presentation with major histocompatibility complex (MHC) to T cells. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)
- polyanhydrides, polyalkylene oxides, and copolymers thereof,
Specification